Anbio Biotechnology
NNNN Healthcare Medical Instruments & Supplies
Anbio Biotechnology’s revenue for fiscal 2025 (year ended December 2025) was $8.6 million, up 5.64% from fiscal 2024.
Follow NNNN
Anbio Biotechnology (NNNN) Altman Z-score
Anbio Biotechnology's Altman Z-score for fiscal 2025 is 8977.35, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 8977.35 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 1.00 | — | 1.20 | |
| Retained earnings / total assets | 0.78 | — | 1.09 | |
| EBIT / total assets | 0.19 | — | 0.63 | |
| Market value of equity / total liabilities | 14,956.91 | — | 8974.15 | |
| Sales / total assets | 0.29 | — | 0.29 | |
| Altman Z-score | Safe zone | 8977.35 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 370.99 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| NNNN Anbio Biotechnology | 8,977× |
| UTMD Utah Medical Products, Inc. compare | 36.3× |
| STAA STAAR Surgical Company compare | 6.4× |
| ZJYL Jin Medical International Ltd. compare | 3.7× |
| SMTI Sanara MedTech Inc. compare | 2.3× |
| EMBC Embecta Corp. compare | 1.8× |
| ANGO AngioDynamics, Inc. compare | 1.6× |
| OSUR OraSure Technologies, Inc. compare | 1.5× |
| AVR Anteris Technologies Global Corp. compare | −31.5× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets